ASD - HIPROS
LIVE

Serial Number

79331573

Owner

Hovione Scientia Limited

Attorney

R. Peter Spies

Filing Date

May 7, 2021

Add to watchlist:

No watchlists yet
View on USPTO

ASD - HIPROS Trademark

Serial Number: 79331573 • Registration: 6932819

ASD - HIPROS is a trademark filed by Hovione Scientia Limited on May 7, 2021. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

Hovione Scientia Limited (16 trademarks)

Loughbeg

Entity Type: 99

Trademark Details

Filing Date

May 7, 2021

Registration Date

December 27, 2022

Published for Opposition

October 11, 2022

Goods & Services

Active pharmaceutical ingredients in the nature of pharmaceutical preparations, which are used for the prevention and treatment of disorders of the skin, musculo-skeletal, cardiac, neurological, cellular, vascular, hematological, respiratory, digestive, genital, urinary, reproductive, sensorial, metabolic, endocrine, lymphatic, immune or nervous systems of humans or animals; compositions for medical and veterinarian use, namely, chemical products for pharmaceutical use, namely, chemical preparations for the prevention, diagnosis, treatment or improvement of conditions and disorders, namely, inflammatory, allergical, oncological, degenerative, genetic, traumatic, tumoural, pressure, poisoning, mutation, sepsis, psychiatric, obese, eating, addictive, sexual, sleep, and infectious conditions and disorders, namely, bacterial, viral, fungal or parasitic conditions and disorders, all of the above related to skin, musculo-skeletal, cardiac, neurological, cellular, vascular, hematological, respiratory, digestive, genital, urinary, reproductive, sensorial, metabolic, endocrine, lymphatic, immune or nervous systems, as well as pain management, for use by humans or animals; medical diagnostic compositions, namely medical diagnostic reagents; chemical products for pharmaceutical use, namely, chemical preparations for the prevention, diagnosis, treatment or improvement of conditions and disorders, namely, inflammatory, allergical, oncological, degenerative, genetic, traumatic, tumoural, pressure, poisoning, mutation, sepsis, psychiatric, obese, eating, addictive, sexual, sleep, and infectious conditions and disorders, namely, bacterial, viral, fungal or parasitic conditions and disorders, all of the above related to skin, musculo-skeletal, cardiac, neurological, cellular, vascular, hematological, respiratory, digestive, genital, urinary, reproductive, sensorial, metabolic, endocrine, lymphatic, immune or nervous systems, as well as pain management, for use by humans or animals

Development of pharmaceutical products and drug products; research on pharmaceutical products and drug products; research and development of new products in the pharmaceutical industry; Consulting services in the field of design and development of engineering processes for the pharmaceutical industry; research in the field of optimizing of manufacturing processes for the pharmaceutical industry

Filing History

NEW REPRESENTATIVE AT IB RECEIVED
Jun 26, 2025 NREP
FINAL DECISION TRANSACTION PROCESSED BY IB
May 10, 2023 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Apr 14, 2023 FICS
FINAL DISPOSITION PROCESSED
Apr 13, 2023 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Mar 27, 2023 FICR
NEW REPRESENTATIVE AT IB RECEIVED
Feb 12, 2023 NREP
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Dec 27, 2022 NRCC
REGISTERED-PRINCIPAL REGISTER
Dec 27, 2022 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Oct 11, 2022 NPUB
PUBLISHED FOR OPPOSITION
Oct 11, 2022 PUBO
NOTIFICATION PROCESSED BY IB
Oct 10, 2022 GPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Sep 21, 2022 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Sep 21, 2022 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Sep 21, 2022 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Sep 8, 2022 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Aug 16, 2022 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Aug 16, 2022 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Aug 16, 2022 TROA
REFUSAL PROCESSED BY IB
Mar 22, 2022 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Feb 28, 2022 RFCS
REFUSAL PROCESSED BY MPU
Feb 28, 2022 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Jan 29, 2022 RFCR
NON-FINAL ACTION WRITTEN
Jan 28, 2022 CNRT
APPLICATION FILING RECEIPT MAILED
Jan 25, 2022 MAFR
ASSIGNED TO EXAMINER
Jan 21, 2022 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jan 21, 2022 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Jan 20, 2022 REPR